RAS LifeScience Solutions’ Post

Exciting developments at #ASCO24 are reshaping the treatment landscape for HER2+ metastatic breast cancer in 2024. Here's a snapshot of the evolving strategies: 1️⃣ First Line: Taxane, Trastuzumab, and Pertuzumab. 2️⃣ Second Line: T-DxD or Tucatinib, Capecitabine, and Trastuzumab. 3️⃣ Third Line: Tucatinib, Capecitabine, and Trastuzumab or T-DM1. 4️⃣ Fourth Line and Beyond: Multiple targeted therapy options including T-DM1, Margetuximab + Chemotherapy, and more. The NCCN Guidelines advocate for re-biopsy and clinical trials to refine treatments further, aiming for personalized and effective therapy for all patients. Let's continue driving progress in oncology with hope and innovation! For more updates, follow our page: https://lnkd.in/de5zNWmK #BreastCancerAwareness #CancerResearch #Oncology #MedicalInnovation #HER2Positive #CancerTreatment #HealthcareInnovation

Merck Group & Kelun LifeSciences (Pvt)Ltd’s TROP-2 ADC could be a ray of hope post Phase III data readout highlighting its efficacy in the most aggressive breast cancer type, TNBC. Sacituzumab tirumotecan, known as SKB264, has demonstrated outstanding potential in the treatment of advanced triple-negative breast cancer (TNBC), substantially lowering the risk of disease progression or mortality while maintaining an acceptable safety profile. An interim analysis conducted on June 21, 2023, indicated that patients treated with SKB264 experienced a median progression-free survival (PFS) of 5.7 months, which is more than twice the 2.3 months observed in patients who received standard chemotherapy. The 6-month PFS rates further highlighted the difference, with SKB264 achieving a rate of 43.4% compared to 11.1% for chemotherapy. In patients exhibiting high TROP2 expression, the median PFS for SKB264 was 5.8 months, significantly longer than the 1.9 months for those on chemotherapy. DelveInsight Business Research LLP's American Society of Clinical Oncology (ASCO) 2024 Exclusive Coverage, Unlock the Best Expert Insights and Comprehensive Analysis @ https://lnkd.in/dmRMbVCf #ASCO24 #ASCO #ASCOconference #SacituzumabTirumotecan #SKB264 #AdvancedTNBCTreatment #CancerTherapyInnovation #ProgressionFreeSurvival #TROP2Expression #BreastCancerTreatment #OncologyBreakthroughs #ChemotherapyAlternatives #CancerSurvivalImprovements #TargetedCancerTherapy #TripleNegativeBreastCancer #CancerResponseRate #MedicalResearchAdvances  #HopeForCancerPatients #PersonalizedOncology #CancerTreatmentOptions

I'm excited to share the findings from our latest study presented in #ASCO2024 by Dr. Shaheenah Dawood from Mediclinic City Hospital, titled "Impact of use of antibody drug conjugates on the prognostic outcome of patients with HR+ve/HER2-ve MBC: Results from a real-world dataset". 💡 This TriNetX study shows significant overall survival (OS) benefits for HR+ve/HER2-ve metastatic breast cancer patients treated with trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG): * T-DXd: 5-year OS of 74.8% vs. 52.2% in control patients. * SG: 5-year OS of 73.4% vs. 64.7% in control patients. * Combined T-DXd + SG: 5-year OS of 77.4% vs. 62.4% in control patients. Read the full abstract in Journal of Clinical Oncology, Volume 42, Number 16_suppl: https://lnkd.in/dj8T_wrP Raman Ghuman Alba Segovia Hilara #BreastCancerResearch #Oncology #RealWorldData

Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions: With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS)1,2 iDFS benefit remains consistent across...

𝐂𝐨𝐮𝐥𝐝 𝐅𝐑𝐔𝐙𝐀𝐐𝐋𝐀™ 𝐫𝐞𝐝𝐞𝐟𝐢𝐧𝐞 𝐦𝐂𝐑𝐂 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭? Takeda's new release, #FRUZAQLA, marks a pivotal shift in metastatic colorectal cancer care. As the first oral therapy targeting all three VEGF receptor kinases, it promises a novel approach for patients who have exhausted other options. The edge? FRUZAQLA™ demonstrated significant gains in both overall and progression-free survival against placebos in Phase 3 trials. This is a new direction for patient care. Why pivot to FRUZAQLA™ now? It offers a chemotherapy-free alternative, crucial for enhancing quality of life in mCRC treatments. This positions FRUZAQLA™ not just as a medication, but as a cornerstone in modern oncology strategies. How will FRUZAQLA™ fit into your current treatment landscape? Share your thoughts! 𝐏.𝐒. 𝐃𝐨𝐧'𝐭 𝐟𝐨𝐫𝐠𝐞𝐭 𝐭𝐨 𝐫𝐞𝐩𝐨𝐬𝐭 ♻️ 𝐭𝐡𝐢𝐬 𝐟𝐨𝐫 𝐨𝐭𝐡𝐞𝐫𝐬. #Cancer #Oncology #Oncolyst #ColorectalCancer 𝐍𝐨𝐭𝐞: This is for education purpose. Please consult your doctor before opting for any treatment.

News SOC in first line mUC advancing by leaps and bounds. Today, 15th december, FDA has approved pembrolizumab plus enfortumab vedotin as 1st line treatment for patients with locally advanced or metastatic urothelial carcinoma, due to EV302/K-A39 phase 3 trial. ✅54.3% cisplatin elegible ✅71.9% visceral metastasis (22.6% liver) ✅mOS 31.5 vs 16.1 m (HR 0.47, 95% CI: 0.38-0.58)➡️HR 0.53 cis-eligible, HR 0.43 cis-ineligible ✅mPFS 12.5 vs 6.3 m (HR 0.45,95% CI: 0.38-0.45) ✅ORR 67.7 vs 44.4% (CR 29.1 vs 12.5%; PD 8.7 vs 13.6%) ✅30.4 % avelumab maintenance control arm ✅22 vs 14% discontinuations ✅AEs G3 and higher: 56 vs 70% Thoughts: 🙌 mOS never previously seen 👁️ 31.5 m from EV302 > 23.8 m (25.3 m in ciseligible population) in JAVELIN100, 29.7 m from start of 1L chemotherapy > 21.7 m (CGnivo-Checkmate901 ciseligible) 🥷Probably we need to get used to AES management and probably there will still be a room for some JAVELIN patients.

🔬 As the fight against cancer becomes increasingly crucial with the expected rise in cases worldwide, Veristat's latest Voyager Newsletter highlights the pioneering ways Veristat is making a difference. Learn how our clients are seeing faster, more hopeful results in their cancer trials. Download now > https://lnkd.in/gm-8DuJd #Veristat #Oncology #Cancer #CRO #ClinicalTrials #Clinical #Regulatory #Biometrics

According to the American Cancer Society, out of the total lung cancer cases, approximately 80─85% of lung cancers are NSCLC. SKB264, a third-generation ADC, in combination with KL-A167, has exhibited promising efficacy in Phase II studies for treatment-naive advanced NSCLC patients. The therapy demonstrated high response rates, favorable disease control, and a manageable safety profile. Get Ahead with Expert Insights and Full Analysis through DelveInsight Business Research LLP's Exclusive ASCO 2024 Coverage! https://lnkd.in/gwXQzR_f #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

We are pleased to announce that US FDA has approved IND for our asset AUR-112, a potent and selective inhibitor of MALT1, being developed for the treatment of lymphoid malignancies. With desirable free fraction and potency in human whole blood assay, AUR-112 may add clinical value to patients. This milestone is a testament to the team's hard work and dedication, reaffirming our commitment to developing innovative therapeutics for cancer patients worldwide. #MALT1 #Oncology #Cancer #DrugDiscovery #INDapprovals #CancerTherapies #CancerDrugs #FDAapprovals #Lymphoma #CancerTreatment #IndiaDrugDiscovery #OncologyPipeline #CancerDrugPipeline #NovelTherapeutics #OncologyTargets

🚀 Bristol Myers Squibb announced that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a potential first-line treatment for adult patients with advanced hepatocellular carcinoma (HCC). 🚀 🔬 The application is supported by promising results from the Phase 3 CheckMate -9DW trial, which demonstrated that Opdivo plus Yervoy significantly improves overall survival (OS) compared to lenvatinib or sorafenib. The safety profile of the combination remains consistent and manageable, with no new safety signals. 🎓 These groundbreaking results were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Bristol Myers Squibb continues to lead the way in advancing cancer treatment and improving patient outcomes. Source: BMS PR, July 19, 2024 #CancerResearch #HCC #MedicalInnovation #Opdivo #Yervoy #BristolMyersSquibb #cancer #oncology